J Pain:慢性疼痛退伍军人阿片类药物和酒精滥用情况

2022-06-25 MedSci原创 MedSci原创

退伍军人酒精和阿片类药物滥用频率与以前的研究报道相一致,大约三分之一滥用阿片类药物,大约五分之一同时滥用两种物质。

慢性疼痛是美国退伍军人寻求治疗的最常见原因之一,高达68%的退伍军人有慢性疼痛的症状。相当大比例的退伍军人服用阿片类药物治疗慢性疼痛。虽然处方率已从2010年初的峰值下降,但最近的估计表明,多达三分之一的退伍军人仍在开具阿片类药物处方。虽然有支持性证据表明,阿片类药物可以减轻慢性疼痛患者的疼痛强度,但也有增加发病率和死亡率的风险。退伍军人可能特别容易受到这些风险的影响,因为在这一人群中,越来越多的人员使用阿片类药物治疗慢性疼痛,并与药物滥用、药物使用障碍、多重用药以及阿片类药物相关的过量死亡的高风险相关。

在美国退伍军人中,慢性疼痛是阿片类药物和酒精滥用的一个风险因素,但很少有研究研究慢性疼痛、阿片类药物处方以及阿片类药物和酒精滥用之间的相互作用。先前的研究发现,在一个服用阿片类药物并伴有慢性疼痛的社区样本中,酒精和阿片类药物滥用出现了并存的风险。

近日,麻醉疼痛领域权威杂志The journal of Pain上发表了一篇研究文章,211名退伍军人在一项针对阿片类药物处方个体的慢性疼痛治疗服务中接受了评估,他们完成了阿片类药物滥用、酒精滥用、疼痛强度、抑郁、疼痛灾难化和创伤后应激症状(PTS)的自我报告。

根据物质滥用指标,32% (n=68)的患者不滥用阿片类药物和酒精,23% (n=48)的患者同时滥用阿片类药物和酒精,40% (n=84)的患者单独滥用阿片类药物,5% (n=11)的患者单独滥用酒精。组间比较表明,未滥用任何一种物质的个体与单独滥用或两种物质都滥用的个体相比,痛苦程度要低一些。后两组在PTS方面有所不同。

总的来说,退伍军人酒精和阿片类药物滥用频率与以前的研究报道相一致,大约三分之一滥用阿片类药物,大约五分之一同时滥用两种物质。有必要更加重视多物质滥用和开发综合治疗策略。

原始出处:

Kevin E. Vowles. et al.Opioid and Alcohol Misuse in Veterans with Chronic Pain: A Risk Screening Study.The journal of Pain.2022.https://www.jpain.org/article/S1526-5900(22)00347-9/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648693, encodeId=d22a16486938c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Wed Dec 07 00:20:22 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701617, encodeId=da5e1e016172c, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Apr 21 09:20:22 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253147, encodeId=9b0e125314edd, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260088, encodeId=208a126008803, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309206, encodeId=c33b1309206a6, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1648693, encodeId=d22a16486938c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Wed Dec 07 00:20:22 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701617, encodeId=da5e1e016172c, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Apr 21 09:20:22 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253147, encodeId=9b0e125314edd, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260088, encodeId=208a126008803, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309206, encodeId=c33b1309206a6, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=)]
    2023-04-21 zchen
  3. [GetPortalCommentsPageByObjectIdResponse(id=1648693, encodeId=d22a16486938c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Wed Dec 07 00:20:22 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701617, encodeId=da5e1e016172c, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Apr 21 09:20:22 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253147, encodeId=9b0e125314edd, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260088, encodeId=208a126008803, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309206, encodeId=c33b1309206a6, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1648693, encodeId=d22a16486938c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Wed Dec 07 00:20:22 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701617, encodeId=da5e1e016172c, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Apr 21 09:20:22 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253147, encodeId=9b0e125314edd, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260088, encodeId=208a126008803, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309206, encodeId=c33b1309206a6, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1648693, encodeId=d22a16486938c, content=<a href='/topic/show?id=718f9464852' target=_blank style='color:#2F92EE;'>#退伍军人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94648, encryptionId=718f9464852, topicName=退伍军人)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9d23641338, createdName=smlt2016, createdTime=Wed Dec 07 00:20:22 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701617, encodeId=da5e1e016172c, content=<a href='/topic/show?id=bedc665998e' target=_blank style='color:#2F92EE;'>#滥用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66599, encryptionId=bedc665998e, topicName=滥用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea1030383785, createdName=zchen, createdTime=Fri Apr 21 09:20:22 CST 2023, time=2023-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253147, encodeId=9b0e125314edd, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260088, encodeId=208a126008803, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309206, encodeId=c33b1309206a6, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Mon Jun 27 02:20:22 CST 2022, time=2022-06-27, status=1, ipAttribution=)]
    2022-06-27 lhlxtx

相关资讯

Brit J Anaesth:慢性疼痛患者长期服用阿片类药物与癌症风险之间的关系

长期使用阿片类药物与慢性疼痛患者发生癌症之间存在相关性,但这需要进一步的研究来明确。

Pain:慢性疼痛与COVID-19住院和死亡率的关系

慢性疼痛与较高的COVID-19住院风险相关,但与死亡率的关联尚不清楚。未来的研究需要进一步调查这些结果,并确定疼痛是否与Covid-19相关。

指南与共识:糖皮质激素在慢性疼痛治疗中应用的专家共识(2020版)

疼痛是一种与组织损伤相关联的、令人不愉快的感觉和情感体验。当疼痛持续存在超过3个月,或超过相关疾病一般病程或损伤愈合所需要的一般时间,即形成慢性疼痛。

用药镇痛一时爽,疼痛期反而延长?Science子刊:用消炎药会导致慢性疼痛风险上升!

Science子刊:在疼痛早期使用抗炎药物镇痛,将导致后期进展为慢性疼痛的风险上升。

Age & Ageing:老年人总是喊疼?阿片类药物对老年人认知功能的影响

老年人中,约有80%的人报告有持续的疼痛。

Lancet rheumatology:全膝关节置换术后3个月疼痛患者的STAR护理途径:一项多中心、务实、随机、对照试验

STAR是一种临床有效且具有成本效益的干预措施,可在全膝关节置换手术后 3个月内改善慢性疼痛患者1年以上的疼痛结果。